Hemogenyx Pharmaceuticals PLC

Research Hemogenyx Pharmaceuticals PLC (HEMO) on Bullrun: market cap GBX 51.85M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerHEMO
• ExchangeLSE
• CountryUnited Kingdom
• SectorHealthcare
• IndustryBiotechnology
• CurrencyGBX
• Market capGBX 51.85M
• Financial periodFY2024
• Net income-GBP 5.62M
• Free cash flow-GBP 4.15M

Valuation Snapshot

latest market cap is GBX 51.85M.

About Hemogenyx Pharmaceuticals PLC

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions;

Frequently asked questions

What is Hemogenyx Pharmaceuticals PLC's market cap?

Hemogenyx Pharmaceuticals PLC's market capitalization is GBX 51.85M.

What does Hemogenyx Pharmaceuticals PLC do?

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States.